Clinical trials: Obese Subjects
Diabetes, Nutrition Disorders
OPTIFIT-Optimal Fiber Trial for Diabetes Prevention
High intake of insoluble fiber is strongly associated with a reduced incidence of diabetes and cardiovascular events in prospective observation studies.
- Conditions
- Diabetes, Nutrition Disorders, Obesity, Overweight
- Trial name
- NCT01681173
- Testing
- Fiber
- Where
- 2 sites in Germany
- Volunteers
- 200 people
- Sponsor
- German Institute of Human Nutrition
Obesity, Non-Alcoholic Fatty Liver Disease
Effect of Timed-Restricted Eating on Metabolic Health
We aim to determine the effect of combined isocaloric time restricted eating and meal timing on metabolic health, liver fat, functional brain networks, inflammation, and sleep pattern/quality in subjects with obesity and insulin…
- Conditions
- Obesity, Non-Alcoholic Fatty Liver Disease, Insulin Resistance
- Trial name
- TREAT (NCT06061042)
- Testing
- Early time restricted eating, Late time restricted eating
- Where
- Netherlands
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Insulin Resistance, Type 2 Diabetes
Fish Gelatin Supplement and Omega-3 Supplement in Obese or Overweight Subjects With Insulin Resistance
The present study was conducted to test whether a fish gelatin supplement combined with an omega-3 polyunsaturated fatty acid supplement can exert beneficial and sex-specific effects on insulin sensitivity, glucose tolerance…
- Trial name
- NCT01215903
- Testing
- Fish gelatin and omega-3 polyunsaturated fatty acid, Omega-3 polyunsaturated fatty acid
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- Laval University
Obesity, Obstructive Sleep Apnea
Long-term Effects of Lipoabdominoplasty on Pulmonary Function and Sleep Apnea Risk in Obese Subjects
This study investigates the long-term effects of lipoabdominoplasty on pulmonary function and obstructive sleep apnea (OSA) risk in obese patients.
- Trial name
- NCT07029750
- Testing
- Lipoabdominoplasty
- Where
- Turkey (Türkiye)
- Volunteers
- 31 people
- Sponsor
- Atlas University
Overweight and Obesity
Extension Study of Gelesis100 on Body Weight
This study is designed to assess the effect of Gelesis100 on body weight after an additional exposure of 24 weeks in subjects who completed the 24-week treatment period, and had at least 3% weight loss, in the Gelesis Loss Of…
- Trial name
- GLOW-EX (NCT03021291)
- Testing
- Gelesis100 (2.25 g)
- Where
- 16 sites in United States, Czechia and 3 more
- Volunteers
- 36 people
- Sponsor
- Gelesis, Inc.
Supplementation, Obesity
Clinical Trial to Analyze the Efficacy of a Supplement Extracted From Persimmon on Overweight / Obesity.
Randomized, controlled, double-blind clinical trial, with two parallel branches depending on the product consumed (experimental product and placebo product) and single-center, to measure the efficacy of a supplement extracted…
- Trial name
- PERSOB (NCT05750342)
- Testing
- Experimental Product Caqui
- Where
- Spain
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Universidad Católica San Antonio de Murcia
Obesity, Nutritional Intervention
Postprandial Blood Cell Transcriptome of Normal Weight and Obese Subjects to 3 Caloric Doses of a High-fat Meal
The study will quantitatively evaluate the metabolic response of normal weight and obese subjects to three high-fat meals differing in caloric dose by analysing the postprandial blood transcriptome.
- Trial name
- NCT01995110
- Testing
- high-fat meal A, high-fat meal B, high-fat meal C
- Where
- 2 sites in Switzerland
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Agroscope Liebefeld-Posieux Research Station ALP
Obesity
Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese Subjects
The main purpose of this study is to examine the effect of prolonged (72 hour) administration of glucagon compared to placebo on energy expenditure in healthy, non-diabetic, obese subjects.
- Trial name
- GIO B (NCT03139305)
- Testing
- Glucagon
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AdventHealth Translational Research Institute
Obesity, Overweight
Efficacy and Safety of IQP-VV-102 in Weight Management
Subjects are randomized to either IQP-VV-102 or a matching placebo. Over 12 weeks, the subjects' body weight, body fat and safety parameters are monitored
- Trial name
- NCT01681069
- Testing
- IQP-VV-102
- Where
- Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Thrombosis
Study Investigation Pharmacokinetics and Pharmacodynamics of CS1
SAD study: Eighteen subjects will be included in the SAD study (single dose) in 3 parallel arms, each with 6 subjects. The 3 arms will receive a single dose of one of the CS1 formulations I, II or III.
- Trial name
- NCT03903302
- Testing
- CS1-Sodium Valproate
- Where
- Sweden
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Cereno Scientific AB
Overweight, Overweight or Obesity
The Effectiveness and Safety of HIIT in Overweight Male Subjects
Increased prevalence of overweight and obesity is one of the main health problems recently. Energy balance from nutrition intake and energy expenditure through physical activity, especially structured physical activity, is needed…
- Trial name
- NCT05000437
- Testing
- HIIT
- Where
- 2 sites in Indonesia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Universitas Indonesia
Obesity
A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide
This is a study of tirzepatide in participants with obesity. The main purpose is to learn more about how tirzepatide affects the number of calories participants burn and the amount of food they eat.
- Trial name
- NCT04081337
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Eli Lilly and Company
Obesity
A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients
The purpose of this study is to determine if CP-945,598 is effective in the treatment of obesity in type 2 diabetic patients.
- Trial name
- NCT00391196
- Testing
- CP-945,598, CP-945,598 Treatment B
- Where
- 91 sites in United States, Argentina and 9 more
- Volunteers
- 975 people
- Sponsor
- Pfizer
Obesity
A Single-dose, Dose-escalation Study of a Long-acting MOD-6031 in Healthy Overweight or Obese Subjects
MOD-6031 is a long-acting reversibly PEGylated oxyntomodulin (OXM) therapeutic. The active moiety is a gastrointestinal neuropeptide with a sequence identical to endogenous human OXM and is an agonist for both glucagon-like…
- Trial name
- NCT02692781
- Testing
- MOD-6031
- Where
- Israel
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- OPKO Health, Inc.
Obesity
Role of Dopamine Transporter in Glucose Control
Healthy subjects will be enrolled in this study. Each subject will be scanned twice with F18-FP-CIT PET which is commercially available. F18-FP-CIT reflects dopamine transporter availability of striatum.
- Trial name
- NCT03466697
- Testing
- Glucose injection/Normal saline injection
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Pusan National University Hospital
Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)), Obesity
Optimized Cardioprotection Therapy in Obese Subjects With CAD
The purpose of this study is to investigate the efficacy and mechanism of Adipokines Cardiac Protection in Obese Patients With coronary artery disease (CAD).
- Conditions
- Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)), Obesity, Adiposis; Heart
- Trial name
- NCT04570527
- Testing
- PCI
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Xijing Hospital
Overweight, Obesity
A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney Function
The study looks at the blood levels of a new study medicine in people with normal and impaired kidney function. Participants will get the study medicine called NNC0174-0833.
- Trial name
- NCT04209049
- Testing
- NNC0174-0833
- Where
- 2 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Weight Loss
VK2735 for Weight Management Phase 2 (Venture Oral Dosing)
This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm dose-finding study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735…
- Trial name
- NCT06828055
- Testing
- VK2735
- Where
- 15 sites in United States
- Volunteers
- 280 people
- Sponsor
- Viking Therapeutics, Inc.
Overweight, Obesity
Safety and Performance Evaluation of the Epitomee Device for Enhancing Satiety and Weight Loss.
Study design to demonstrate the safety and performance of the Epitomee Device
- Trial name
- NCT03610958
- Testing
- Epitomee Device
- Where
- Israel
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Epitomee medical
Obesity, Eating Disorders
Food Addiction and Follow-up in Subjects With Obesity
Obesity is a chronic disease. Its prevalence, which is constantly increasing, as well as the morbidity and mortality caused, require the development of new treatments, particularly for associated eating disorders.
- Conditions
- Obesity, Eating Disorders, Food Addiction
- Trial name
- ADDICTAL (NCT04218097)
- Testing
- Study questionnaire
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Hospices Civils de Lyon